Werbung... TITAN PHARMACEUTICALS (WKN: 914404 oder ISIN: US8883141017)wäre eine Investion wert. Kennt jemand diesen Wert bzw. kann jemand das Portfolio realistisch einschätzen?!
Was ich jedenfalls interessant finde sind die strategischen Partnerschaften mit Schering und Novartis.
Titan Pharmaceuticals, Inc. (TTP) is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. As of June 30, 2002, the company has ten products in development, seven of which are in clinical development, with two products in expanded human trials for safety and efficacy, known as Phase III clinical trials. TTP has five products in earlier stage trials for dosing, and preliminary safety and efficacy, known as Phase I and Phase II clinical trials. In addition to these programs, it has three products in pre-clinical development. TTP conducts a small portion of its operations through two subsidiaries: 81%-owned Ingenex, Inc. and 79%-owned ProNeura, Inc. Ingenex is engaged in the development of gene-based therapeutics for the treatment of cancer. ProNeura develops cost effective, long-term treatment solutions to neurologic and psychiatric disorders through an implantable drug delivery system. TTP is independently developing its product candidates and also utilizing strategic partnerships, including collaborations with Novartis Pharma AG and Schering AG, as well as collaborations with several government-sponsored clinical cooperative groups. These collaborations help fund product development and enable the company to retain significant economic interest in its products. The company's lead CNS therapeutic product candidate, iloperidone, is being developed for the treatment of schizophrenia, the most common form of psychosis. As of Dec. 31, 2001, Iloperidone is being evaluated in an extensive Phase III program administered by Novartis comprising over 3,500 patients at more than 200 sites in 24 countries. TTP's products are at various stages of development and may not be successfully developed or commercialized. The company does not have any products being sold on the commercial market. Its proposed products will require significant further capital expenditures, development, testing, and regulatory clearances prior to commercialization. The company may experience unanticipated problems relating to product development and cannot predict whether it will successfully develop and commercialize any products.
Gruss Mario Huana
Was ich jedenfalls interessant finde sind die strategischen Partnerschaften mit Schering und Novartis.
Titan Pharmaceuticals, Inc. (TTP) is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. As of June 30, 2002, the company has ten products in development, seven of which are in clinical development, with two products in expanded human trials for safety and efficacy, known as Phase III clinical trials. TTP has five products in earlier stage trials for dosing, and preliminary safety and efficacy, known as Phase I and Phase II clinical trials. In addition to these programs, it has three products in pre-clinical development. TTP conducts a small portion of its operations through two subsidiaries: 81%-owned Ingenex, Inc. and 79%-owned ProNeura, Inc. Ingenex is engaged in the development of gene-based therapeutics for the treatment of cancer. ProNeura develops cost effective, long-term treatment solutions to neurologic and psychiatric disorders through an implantable drug delivery system. TTP is independently developing its product candidates and also utilizing strategic partnerships, including collaborations with Novartis Pharma AG and Schering AG, as well as collaborations with several government-sponsored clinical cooperative groups. These collaborations help fund product development and enable the company to retain significant economic interest in its products. The company's lead CNS therapeutic product candidate, iloperidone, is being developed for the treatment of schizophrenia, the most common form of psychosis. As of Dec. 31, 2001, Iloperidone is being evaluated in an extensive Phase III program administered by Novartis comprising over 3,500 patients at more than 200 sites in 24 countries. TTP's products are at various stages of development and may not be successfully developed or commercialized. The company does not have any products being sold on the commercial market. Its proposed products will require significant further capital expenditures, development, testing, and regulatory clearances prior to commercialization. The company may experience unanticipated problems relating to product development and cannot predict whether it will successfully develop and commercialize any products.
Gruss Mario Huana
